Short Communication

Clinical presentations and outcomes of SARS-CoV-2 infected pneumonia in pregnant women and health status of their neonates

Luming Xu a,1, Qianqian Yang a,1, Haojun Shi e,1, Shijun Lei a,1, Xiaoli Liu f, Ying Zhu b, Qiulei Wu b, Xiuli Ding a, Yanhong Tian g, Qinghua Hu d, Fenghua Chen a, Zhi Geng a, Xiangzi Zeng b, Lin Lin b, Xuehong Cai b, Min Wu b, Zehua Wang b,e, Zheng Wang c,e, Geqing Xia b,e, Lin Wang a,*

a Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
b Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
c Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
d Department of Respiratory Pathophysiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
e Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
f Department of Obstetrics and Gynecology, The First People’s Hospital of Tianmen, Tianmen 431700, China

Article info

Article history:
Received 28 February 2020
Received in revised form 13 April 2020
Accepted 20 April 2020
Available online 28 April 2020
© 2020 Science China Press. Published by Elsevier B.V. and Science China Press. All rights reserved.

The outbreak of COVID-19 has affected the world greatly. While much remains unknown, the severity of the illness is quite alarming. The disease outbreak is still ongoing with a rapidly growing number of patients. With confirmed human-to-human transmission, this disease has put pregnant women at risk, endangering the lives of infected mothers and their babies. However, current data so far have been mainly focused on general population but not for these patients, and we were not sure if SARS-COV-2 can be vertical transmitted from mothers to their babies. Here, we report the clinical, laboratory, radiological profiles and treatment outcomes of these five COVID-19 pregnant women and provide clinical information of their neonates.

For this retrospective study, five pregnant women were admitted from Jan 21, 2020 to Feb 9, 2020 by Wuhan Union Hospital. All pregnant patients were >34 week pregnancy with fever or respiratory symptoms. As a result of laboratory confirmation of SARS-CoV-2 infection (Tables 1 and S1 online), all of them were laboratory-confirmed SARS-CoV-2 positive by real-time reverse-transcription PCR (RT-PCR). The clinical features, laboratory and radiological findings, therapeutic methods and outcomes for all the five patients and their neonates were obtained, recorded and carefully analyzed. All data were checked by three researchers. This study was approved by Wuhan Union Hospital Ethics Committee and informed consent was obtained.

Between Jan 21, 2020 and Feb 9, 2020, five pregnant women were admitted with laboratory-confirmed SARS-CoV-2-infection (Tables 1 and S1 online). None of them had Huanan seafood market exposure (Table 1) and all the patients were residents of Wuhan. According to patients’ records, only Patient 4’s family member was confirmed with SARS-CoV-2 before onset of her symptoms, and the others did not have close contact with COVID-19 patients within 14 days before symptoms’ onset. These patients were aged between 23 and 34 years (average 29 years) (Table 1), all of their fetuses were healthy and had normal development during pregnancy. Patient 1 was initially admitted due to obstetric reasons, while Patients 2–5 were admitted due to symptoms such as fever and dry cough (Table 1). During clinical course...
Table 1
Clinical features of the pregnant women with COVID-19 pneumonia.

| Patient | Age (year) | Sex | Gestational age at admission (weeks + days) | Pregnancy/birth | Huanan seafood market exposure | Reasons for hospitalization | Chronic illness | Initial symptoms | Severity of pneumonia | 24 h before to 72 h after onset of parturition | Oxygen support | Duration of fever (day) | Days from illness onset to dyspnoea | Diagnosis method | Days from admission to SARS-CoV-2 detection | Surgical indications | Delivery mode | Time between symptom onset and neonate delivery (day) | Antibiviral therapy | Antibiotic therapy | Corticosteroid |
|---------|-----------|-----|---------------------------------------------|------------------|-------------------------------|-----------------------------|-----------------|-----------------|-------------------|---------------------------------------------|---------------|----------------------|----------------------|----------------|--------------------------|----------------|--------------|--------------------------|----------------|----------------|---------------|
| 1       | 34        | Female | 38 weeks + 6 days | 1/0              | No                           | Wait for parturition, abdominal pain | No              | Fever           | Mild               | Antepartum 24 h / Postpartum 72 h | No | 7                   | None                 | Real-time PCR | 5                        | 39 weeks pregnant, abdominal pain | Cesarean section | 6 | Yes                  | Yes               | Yes           | No            |
| 2       | 25        | Female | 34 weeks + 4 days | 1/0              | No                           | Pregnancy with viral pneumonia | No              | Fever           | Mild               | Antepartum 24 h / Postpartum 72 h | No | 2                   | None                 | Real-time PCR | 2                        | Viral pneumonia | Cesarean section | 11                  | Yes           | Yes           | Yes            |
| 3       | 23        | Female | 37 weeks + 3 days | 2/0              | No                           | Pregnancy with viral pneumonia | No              | Fever           | Mild               | Antepartum 24 h / Postpartum 72 h | No | 4                   | None                 | Real-time PCR | 0                        | Viral pneumonia | Cesarean section | 0                   | Yes           | Yes           | Yes            |
| 4       | 34        | Female | 36 weeks + 4 days | 5/1              | No                           | Pregnancy with viral pneumonia | No              | Fever           | Mild               | Antepartum 24 h / Postpartum 72 h | No | 11                  | None                 | Real-time PCR | 1 day before admission| Viral pneumonia | Cesarean section | 10                  | Yes           | Yes           | Yes            |
| 5       | 28        | Female | 37 weeks           | 1/0              | No                           | Fever, colporrhagia       | No              | Fever           | Mild               | Antepartum 24 h / Postpartum 72 h | No | 8                   | None                 | Real-time PCR | 3                        | Eutocia     | Cesarean section | 8                   | Yes           | Yes           | Yes            |

ND: not detected; NA: not available.
of COVID-19 infection, the other symptoms included fatigue and dyspnea (Table 1). Fever was the most common symptom, and could be intermittent, lasting for a median duration of 8 days (range 2–11 days) (Table 1). Dry cough was significant, often aggravated by supine position.

According to the definition of illness severity by WHO interim guideline for COVID-19 [3], all the patients developed mild pneumonia and gave birth to babies during hospitalization (Table 1). The time from the onset of symptoms to delivery for these patients was 6, 10, 5, and 8 days, respectively. Their indicators for baby delivery were: Patient 1 (39 weeks) received C-section due to abdominal pain; Patient 2 (34 weeks + 4 days), Patient 3 (37 weeks + 3 days) and 4 (36 weeks + 4 days) were physiologically ready for parturition through C-section; Patient 5 (37 weeks) had natural laboring due to colporrhagia. None of them had pregnancy terminated due to uncorrectable hypoxemia.

Lymphopenia (<1.1 × 10^9/L) and eosinopenia (<0.02 × 10^9/L) were noted in all the patients at the onset of fever. The timing of eosinopenia largely matched that of lymphopenia. Lymphopenia and eosinopenia could persist until patients’ illness clinically and radiographically improved after antiviral/antibacterial treatment. In contrast, leukopenia was observed in only one patient (Patient 1). Moreover, Patients 2 and 3 had anemia (Table S1 online). All the patients had decreased albumin, and increased CRP and D-dimer levels (Table S1 online), and all the patients were tested negative for other common respiratory infection pathogens (influenza A and B, respiratory syncytial virus, adenoviruses, cosackie virus, chlamydia pneumonia, and mycoplasma pneumonia) (Table S1 online).

All five patients were subjected to chest CT examination 2–7 days (median 6 days) after the onset of fever (Fig. S1 online), and plumbic suits were covered on their abdomens to protect the fetuses. The CT imaging showed bilateral pneumonia in all five patients with characteristic flake-like or regional ground-glass opacity in segments or lobes (Fig. S1 online, Table S1 online). The opacity was often associated with peripheral lung with no clear subpleural sparing. The CT findings were consistent with early reports [5,6].

We recorded and analyzed the treatment of five patients (Table S2 online). Notably, Patients 1–5 gave birth to five neonates with the weight ranging from 2.45 to 3.76 kg (Table 2). None of neonates display respiratory infection-related symptoms, including fever, cough, polypnea, dyspnea, cyanosis of lips, and tri-retrac sign at birth. The Apgar scores ranged 7–8 for 1 min, 8–9 for 5 min, and 10 for 10 min (Table 2). Once they were born, the neonates were separated from their mothers without breast feeding. The neonate of Patient 1 but not the other neonates had scattered skin rashes in face and body, which was reduced in the next day and gradually disappeared within 7 days. The throat swab specimens from all five neonates were collected at 8, 1, 8, 1, 0 days after birth, respectively, and were all SARS-CoV-2 PCR tested negative (Table 2). According to our observation, as of Feb 24, none of these neonates developed any respiratory or systemic symptoms (10–33 days after birth), which were much longer than the currently reported SARS-CoV-2 incubation time (4.1–7.0 days, 95% confidence interval) [7].

SARS-CoV-2, a new member of the coronavirus family, is a newly identified single stranded RNA virus. Similar to SARS-CoV and MERS-CoV, it can cause severe respiratory illness in infected humans [8–10]. Early studies revealed that female patients accounted for 32%–44% of SARS-CoV-2-infected population [5,7]. Although our pregnant COVID-19 patients (average 29 years, Table 1) were younger than affected general adults (average 56 years) [4], they were vulnerable given their immune tolerant conditions during pregnancy [11–13]. Given that Wuhan has an estimated 120 thousands pregnant women annually [14], approximately 20,000 of them were currently under COVID-19 infection threat. Given the estimated size doubling-time 7.4 days [7] and the nationwide confirmed over 77,000 cases (as of Feb 24), more pregnant women are expected to be diagnosed. To provide more information on the management of pregnant COVID-19 patients and the vertical transmission of SARS-CoV-2, in this study, we retrospectively analyzed the clinical features of pregnant women with SARS-CoV-2-infected pneumonia and health conditions of their neonates.

Our data revealed some similarities and differences of these pregnant patients compared to general adults. The spectra of symptoms (100% fever vs. 82% fever), the rate of conventional oxygen support (100% vs. 89%), the rate of antiviral treatment (100% vs. 76%), the percentage of patients with increased CRP (100% vs. 86%), and the CT imaging characteristics in these pregnant patients were largely comparable

Table 2

| Clinical features and outcomes of the five neonates. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Neonates**    | **Patient 1's** | **Patient 2's** | **Patient 3's** | **Patient 4's** | **Patient 5's** |
| SARS-CoV-2 detection (throat swab specimen PCR) | Negative     | Negative     | Negative     | Negative     | Negative     |
| Days from birth to SARS-CoV-2 detection | 8            | 1            | 8            | 1            | 0            |
| Sex              | Male          | Female       | Male          | Male          | Male          |
| Gestational age at admission | 39 weeks    | 34 weeks + 4 days | 37 weeks    | 36 weeks    | 37 weeks    |
| Delivery         | Cesarean      | Cesarean     | Cesarean     | Cesarean     | Cesarean     |
| Reason for delivery | Abdominal pain | Viral pneumonia | Obstetric cause | Viral pneumonia | Obstetric cause, viral pneumonia |
| Amniotic fluid   | Normal        | Normal       | Polyhydramnios | Normal       | Normal       |
| Umbilical cord   | Normal        | Normal       | Normal       | Normal       | Normal       |
| Placenta         | Slight placental separation | Normal | Total placenta praevia | Normal | Normal |
| Neonatal death   | No            | No           | No           | No           | No           |
| Birth weight (kg) | 3.05          | 2.58         | 3.76         | 2.45         | 3.12         |
| Development      | Rashes in face and body | Normal | Normal | Normal | Normal |
| Appearance (Score 2) | 1-5-10 min: 1-2-2 | 1-5-10 min: 1-2-2 | 1-5-10 min: 1-2-2 | 1-5-10 min: 1-2-2 | 1-5-10 min: 1-2-2 |
| Griname (Score 2) | 1-5-10 min: 2-2-2 | 1-5-10 min: 2-2-2 | 1-5-10 min: 2-2-2 | 1-5-10 min: 2-2-2 | 1-5-10 min: 2-2-2 |
| Respiration (Score 2) | 1-5-10 min: 2-2-2 | 1-5-10 min: 2-2-2 | 1-5-10 min: 2-2-2 | 1-5-10 min: 2-2-2 | 1-5-10 min: 2-2-2 |
| Pulse (Score 2)   | 1-5-10 min: 1-1-2 | 1-5-10 min: 2-2-2 | 1-5-10 min: 2-2-2 | 1-5-10 min: 2-2-2 | 1-5-10 min: 2-2-2 |
| Activity (Score 2) | 1-5-10 min: 2-2-2 | 1-5-10 min: 1-2-2 | 1-5-10 min: 1-2-2 | 1-5-10 min: 1-2-2 | 1-5-10 min: 1-2-2 |
| Apgar score (Score 10) | 1-5-10 min: 8-9-10 | 1-5-10 min: 8-9-10 | 1-5-10 min: 7-8-10 | 1-5-10 min: 8-9-10 | 1-5-10 min: 8-9-10 |
to general adults (Table 1) [5,6]. In contrast, these women had less underlying diseases than general adults, and exhibited differences in some biochemical markers. Increased D-dimer levels and lymphopenia were observed in all the patients (100%), higher than 36% and 35% in general adults, respectively (Table S1 online) [5]. These laboratory differences might be partly due to pregnancy-associated physiological alterations.

Eosinopenia was found to be tightly linked with lymphopenia, which was not reported in early COVID-19 literature [5–7], and in SARS-CoV and MERS-CoV infections [15,16]. In COVID-19 pneumonia, eosinopenia appeared early, at the onset of fever, with a significant reduction (Table S1 online). Although eosinopenia was reportedly observed in some pregnant women previously [17], such a drastic decrease in eosinophil counts (reduced to zero in four of five patients) was unusual. Given that lymphopenia was suggestive of diagnosis value for COVID-19 infection [5] and did not commonly appear in normal pregnant women [18], eosinopenia with early timing feature might be also useful for facilitating early diagnosis. Given that glucocorticosteroids were considered to be one of the major reasons accounting for reduction in the number of eosinophils [19,20], it is possible that COVID-19-infection influences the levels of endogenous glucocorticosteroids.

SARS-CoV and MERS-CoV were reported to result in severe complications during pregnancy [19,20]. In a 12-case study [21], the 2003 SARS-CoV reportedly caused the death of three women, miscarriage (57%, 4 of 7 first-trimester patients), fetal growth restriction (40%, 2 of 5 third trimester patients), and premature birth (80%, 4 of 5 patients). As for MERS-CoV, it caused even more detrimental outcomes with 91% women (10 of 11 patients) having poor outcomes and 82% neonates having critical conditions and even death [22]. In this study, all the COVID-19 infected patients gave safe birth. The neonates were immediately separated from their mothers once they were born. The skin rashes were observed in one (20%) of the five neonates (Patient 1) (Tables 1 and 2). From the birth of these neonates until now, none of these babies developed any respiratory systems or pneumonia-associated symptoms. They seemed not to be locally or systemically impacted by COVID-19 infection in their mothers. This was similarly observed for other coronaviruses, such as SARS-CoV and MERS-CoV-infected mothers and their infants [21,23,24]. All neonates' throat swabs were PCR tested negative (Table 2). Thus, collectively, our observations did not support vertical virus transmission between these five infected mothers and their babies, consistent with a recent study [1]. Meanwhile, to protect neonates from SARS-CoV-2 infections after birth, we recommend prevention measures as follows: the neonates should be immediately isolated for a 14-day medical observation; breast feeding should be avoided; a 14-day isolation is also required for their mothers after discharge.

This study is limited in several aspects. Due to shortage of diagnostics reagents in local hospitals at the early stage of this COVID-19 outbreak, the laboratory-confirmed patient number was not high. But all patients and neonates in the current study were tested with PCR. Although we did not observe vertical transmission in these patients and their neonates, more evidence and further study is still required for further validation. Due to the lack of SARS-CoV-2 antibody detection reagents during this study, the serum IgM of SARS-CoV-2 antibody detection reagents in neonates, which was a key indicator of new SARS-CoV-2 infection, was not detected. The nucleic acid of SARS-CoV-2 in peripheral blood of these patients was also not detected due to the lack and control of RT-PCR reagents at the early stage of COVID-19 epidemic in Wuhan. Although the COVID-19 putative receptor ACE2 is critical to virus infection [25], its expression and abundance in neonates’ respiratory system remains unknown. All these questions still await future study. Additionally, the long-term follow-up is needed to evaluate physical and psychological development of these neonates.

In this study, we provided clinical features of SARS-CoV-2 infected women and reported health status of their fetuses. We observed no obvious vertical transmission between these mothers and their neonates, and suggested that immediate prevention measures should be taken for these patients and their neonates to avoid SARS-CoV-2 infections after birth. Lymphopenia and eosinopenia that were uncommon in normal pregnant women were observed at the onset of SARS-CoV-2 related symptoms, which might facilitate early recognition of COVID-19.

Conflict of interest

The authors declare that they have no conflict of interest.

Acknowledgments

We would like to thank all healthcare workers who work in the frontline combatting against COVID-19, and all doctors and nurses who helped these SARS-CoV-2 infected women safely delivered their babies. This work was supported by the National Natural Science Foundation of China (81974382), the Major Scientific and Technological Innovation Projects in Hubei Province (2018ACA136) and COVID-19 Program of Huazhong University of Science and Technology (2020kyGXCJ099).

Author contributions

Luming Xu, Qianqian Yang, Shijun Lei and Haojun Shi contributed equally to this work. Lin Wang, Qingxia Xia, Zheng Wang and Zehua Wang designed and supervised the study. All the authors contributed to collection of epidemiological, clinical and laboratory data. Qingxia Xia, Zheng Wang, Lin Wang, Luming Xu, and Qianqian Yang analyzed and interpreted the data. Luming Xu collected the clinical data and revised the manuscript. Qianqian Yang and Shijun Lei collected and analyzed the laboratory data and prepared the tables. Haojun Shi collected and analyzed the radiology data and revised the manuscript. Lin Wang and Qingxia Xia provided the information of patients, participated in data analysis, drafted and revised the manuscript. Zheng Wang analyzed and interpreted the data, drafted and revised the manuscript. Zehua Wang also has equally contributions to the data analyses and manuscript preparing.

Appendix A. Supplementary materials

Supplementary materials to this article can be found online at https://doi.org/10.1016/j.scib.2020.04.040.

References

[1] Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020;395:809–15.
[2] National Institute for Viral Disease Control and Prevention. Specific primers and probes for detection 2019 novel coronavirus. https://ivdc.chinacdc.cn/kqyj/202001/20200121_211337.html. Accessed January 21, 2020.
[3] World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (COVID-19) infection is suspected. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance. Accessed January 28, 2020.
[4] National Health Commission of China. Clinical Diagnosis and treatment Guideline of 2019 novel coronavirus (COVID-19) caused pneumonia (6th edition). http://www.nhc.gov.cn/xcs/zhengwjw/202002/8334a8326dd94d329df351d7da8aefc2.shtml. Accessed February 19, 2020.
[5] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.
[6] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:487–506.
Zhu N, Zhang D, Wang W, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. New Engl J Med 2020;382:1199–207.

Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. New Engl J Med 2003;348:1967–76.

Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. New Engl J Med 2012;367:1814–20.

Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 2018;23:130–7.

Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome coronavirus (SARS-CoV) infection during pregnancy: report of two cases & review of the literature. J Microbiol Immunol Infect 2019;52:501–3.

Li AM, Ng PC. Severe acute respiratory syndrome (SARS) in neonates and children. Arch Dis Child Fetal Neonatal Ed 2004;191:292–7.

Alfaraj SH, Al-Tawfiq JA, Memish ZA. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection during pregnancy: report of two cases & review of the literature. J Microbiol Immunol Infect 2019;52:501–3.

Qianqian Yang is a technologist-in-charge in Department of Clinical Laboratory at Union Hospital, Huazhong University of Science and Technology. She graduated from Huazhong University of Science and Technology in 2015 with a Ph.D. degree and major in Clinical laboratory diagnostics. Her research interests focus on clinical molecular biology technology and cancer immunology.

Haojun Shi received his M.D. degree in nuclear medicine from Huazhong University of Science and Technology. He is an associate professor in the Department of Radiology at Union Hospital, Huazhong University of Science and Technology. His research direction focuses on the utilizing MRI imaging for head, neck and central nervous system diseases.

Shijun Lei graduated from Huazhong University of science and technology at 2019, and now works in Department of Clinical Laboratory at Union Hospital, Huazhong University of Science and Technology. He focuses on the study of tumor invasion and metastasis by using multi-omics sequencing technology.

Luming Xu received his Ph.D. degree from Huazhong University of Science and Technology and was a post-doctoral fellow from 2016 to 2018. He is presently a research fellow in Research Center for Tissue Engineering and Regenerative Medicine in Union Hospital, Huazhong University of Science and Technology. His research mainly focused on the applications of genomic, bioinformatic and bioengineering technologies in gastrointestinal diseases.

Zehua Wang is the director of the Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, who has devoted himself to clinical and scientific work for over 30 years. His research interests focus on gynecologic oncology, in particular the mechanisms underlying metastasis and drug-resistance of gynecological cancers.
Zheng Wang is a professor and associate-director for the Department of Gastrointestinal Surgery at Union Hospital, Huazhong University of Science and Technology. He received his M.D. degree from Huazhong University of Science and Technology, and Ph.D. degree from Duke University. His research interests include mechanisms study of cancer invasion and metastasis, nanomedicine for antitumor drugs and precision therapies for gastric and colorectal cancer.

Geqing Xia is a chief physician and associate professor in Obstetrics Department at Union Hospital, Huazhong University of Science and Technology. She received her M.D. degree from Huazhong University of Science and Technology. She was a visiting scholar in Vanderbilt University Medical Center. Her main research direction is twin pregnancy, fetal Eugenia and prenatal diagnosis.

Lin Wang is the director of Department of Clinical Laboratory/ director of Research Center for Tissue Engineering and Regenerative Medicine at Union Hospital, Huazhong University of Science and Technology. Her main research interests include the application of natural biomaterials in tissue engineering and regenerative medicine, biomaterial based immunotherapy and molecular diagnostics.